EFX
61
3
CAG
55
2
SE
74
3
CLX
68
2
XEL
71
4
AVGO
35
-17
DNB
60
2
HRB
49
13
HP
28
-12
CHRW
65
5
PVH
37
2
PM
68
6
IFF
50
8
URI
48
8
ZTS
16
4
CMI
52
11
VFC
34
-10
TXN
40
7
ITW
37
-11
NOC
45
-2
EFX
61
3
CAG
55
2
SE
74
3
CLX
68
2
XEL
71
4
AVGO
35
-17
DNB
60
2
HRB
49
13
HP
28
-12
CHRW
65
5
PVH
37
2
PM
68
6
IFF
50
8
URI
48
8
ZTS
16
4
CMI
52
11
VFC
34
-10
TXN
40
7
ITW
37
-11
NOC
45
-2
Financhill
Back

MoonLake Immunotherapeutics Stock Predictions

The Tariff-Proof Asset in Your Pocket

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
27

MLTX
MoonLake Immunotherapeutics

Last Price:
$39.59
Seasonality Move:
-6.98%

7 Day Trial

ALL ACCESS PASS

$ 7

Economy going through a "period of transition" - Your portfolio doesn't have to

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

MoonLake Immunotherapeutics Stock Forecast

  • Over the next 52 weeks, MoonLake Immunotherapeutics has on average historically risen by 52.8% based on the past 4 years of stock performance.
  • MoonLake Immunotherapeutics has risen higher in 2 of those 4 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%
  • Is MoonLake Immunotherapeutics Stock Undervalued?
    The current MoonLake Immunotherapeutics [MLTX] share price is $38.67. The Score for MLTX is 27, which is 46% below its historic median score of 50, and infers higher risk than normal.
  • MLTX is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.

Will MoonLake Immunotherapeutics Stock Go Up Next Year?

  • Over the next 52 weeks, MoonLake Immunotherapeutics has on average historically risen by 52.8% based on the past 4 years of stock performance.

MoonLake Immunotherapeutics Stock Rating

Sell
27
MoonLake Immunotherapeutics (MLTX) is a Sell

Is MoonLake Immunotherapeutics overpriced?

  • MoonLake Immunotherapeutics has risen higher in 2 of those 4 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%

MoonLake Immunotherapeutics Stock Price History

Is MLTX stock going to rise?

  • Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and MLTX is experiencing slight selling pressure.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
Switzerland
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
moonlaketx.com

52-Week Data

52-Week High:
58.26
52-Week Low:
36.52

Prediction Charts

Market Cap:
2.4B
Price in USD:
38.67
Volume:
568.7K
Beta:
1.32

Technical Analysis

SMA50:
44.33
SMA100:
47.75
SMA200:
46.83
52-Wk Change:
-18.16%

Stock Predictions

  • Is MoonLake Immunotherapeutics stock public?
    Yes, MoonLake Immunotherapeutics is a publicly traded company.
  • What is the MoonLake Immunotherapeutics stock quote today?
    The MoonLake Immunotherapeutics stock price is 38.67 USD today.
  • How to buy MoonLake Immunotherapeutics stock online?
    You can buy MoonLake Immunotherapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Feb-25 40.88 40.73 41.36 39.87
Feb-26 40.07 42.37 42.91 40.04
Feb-27 41.93 41.84 43.41 41.78
Feb-28 42.12 41.76 42.56 40.66
Mar-3 41.75 39.63 42.51 39.61
Mar-4 39.50 40.18 40.99 38.83
Mar-5 40.45 39.90 40.66 39.50
Mar-6 39.50 39.75 40.59 39.10
Mar-7 39.74 38.04 40.17 37.91
Mar-11 36.69 37.67 38.03 36.52
Mar-12 38.25 39.31 39.83 37.81
Mar-13 39.25 37.82 39.44 37.73
Mar-14 38.00 38.67 39.20 37.84
Mar-17 38.76 38.67 39.98 37.70

MoonLake Immunotherapeutics Earnings

MoonLake Immunotherapeutics Earnings Report: Per Share MoonLake Immunotherapeutics Earnings Q1 Q2 Q3 and Q4 last year and next year.

MoonLake Immunotherapeutics Forecast Revenue Growth

MoonLake Immunotherapeutics Stock Analysis: Historical quarterly revenues per share for MoonLake Immunotherapeutics and historical quarterly revenue growth:

  • Analysts estimate an earnings decrease this quarter of $0.32 per share, a decrease next quarter of $0.03 per share, a decrease this year of $1.42 per share, and a decrease next year of $0.47 per share.

* MoonLake Immunotherapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.